Skip to main content

Table 2 Effect of IL-1β treatment in in vitro chondrosarcoma culture

From: In vitro suppression of the MMP-3 gene in normal and cytokine-treated human chondrosarcoma using small interfering RNA

 

48 h

 

72 h

 
 

Non-IL1

IL-1

Non-IL1

IL-1

Cell morphology

    

Viability rate

93.05 ± 4.23

46.41 ± 6.04*

93.87 ± 3.44

26.52 ± 5.97*

Apoptosis rate

2.28 ± 1.71

63.39 ± 11.43*

4.62 ± 1.72

70.73 ± 5.02*

Mitotic rate

9.42 ± 2.43

1.36 ± 0.90*

16.22 ± 7.62

0.85 ± 0.30*

Proteoglycan production

   

HA (ng/ml)

121.04 ± 23.03

48.54 ± 12.85*

146.04 ± 11.93

35.29 ± 8.54*

GAG (μg/ml)

1.91 ± 0.88

0.56 ± 0.14*

1.72 ± 0.81

0.17 ± 0.07*

Relative gene expression

   

MMP-3

0.98 ± 0.07

2.03 ± 0.23*

1.56 ± 0.18

2.94 ± .019*

TIMP-3

1.01 ± 0.03

0.57 ± 0.21*

1.35 ± 0.09

0.34 ± 0.06*

HAS-1

1.02 ± 0.13

0.37 ± 0.15*

1.35 ± 0.10

0.15 ± 0.07*

HAS-2

1.02 ± 0.11

0.10 ± 0.04*

1.18 ± 0.12

0.05 ± 0.04*

AGG

1.01 ± 0.06

0.43 ± 0.18*

1.35 ± 0.10

0.17 ± 0.03*

COL2A1

1.02 ± 0.11

0.15 ± 0.10*

1.48 ± 0.14

0.03 ± 0.08*

  1. A significant difference (p < 0.05) between treatment and non-treatment with IL-1β at the same period (48 or 72 h) is displayed with superscript (*) on the number.